CEO and Board Member
Dr. Shehnaaz Suliman is CEO of ReCode Therapeutics – a leading genetic medicines company focused on powering the next wave of genetic medicines through tissue-specific lipid nanoparticle delivery. Dr. Suliman is a physician, drug-developer, company builder and has played a leading role over 25 years in transforming high growth companies through advancing clinical pipelines and executing partnerships and acquisitions at Alector, Theravance, Genentech, Roche and Gilead. Dr. Suliman has been honored by Forbes, Fierce Biotech, Silicon Valley Biz Journal and SF Business times as a nationally acclaimed leader female business leader and advocate for healthcare equity and access. She received her M.D. at the University of Cape Town Medical School, South Africa, and holds an M.B.A, with distinction, and M.Phil. degrees from Oxford University, where she was a Rhodes Scholar. Dr. Suliman serves on the Ultragenyx Pharmaceutical and 10x Genomic Boards. Dr. Suliman is forging paths for under-represented individuals with the Board Room Ready program and is a mentor to dozens of rising stars.